Bridging innovation and clinical impact: advances and challenges in beta cell replacement therapies

This letter explores recent innovations and challenges in beta cell replacement therapies for diabetes, emphasizing the gap between promising bioengineering techniques and clinical applicability. While advancements like stem cell-derived beta cells and bioartificial pancreas models show potential, concerns remain regarding immune rejection, maturation of beta cells, and long-term safety. Current strategies lack focus on type 2 diabetes, which constitutes the majority of cases. Moreover, issues such as vascularization, fibrosis, and ethical implications require further exploration. Bridging scientific breakthroughs with real-world application necessitates rigorous preclinical validation and scalability strategies to ensure safe, effective, and inclusive treatment for the global diabetic population.